课题基金 / 基金详情

B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection

B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection
预防和根除 SIV/SHIV 感染的 B 和 T 细胞生物学
批准号:
9922663
负责人:
Rama Rao Amara
金额:
$663.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-01 至 2023-05-31

项目摘要

项目成果

Rama Rao Amara的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): The Emory Consortium for Innovative AIDS Research in Nonhuman Primates aims to understand the B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection. The consortium brings together an interdisciplinary mix of highly collaborative, and productive investigators in a range of HIV vaccine and cure disciplines to address the overarching hypothesis that a successful prophylactic HIV vaccine will require a strong and sustained systemic and mucosal immune response, comprised of functionally targeted antibody and tissue resident CD8 T cell immunity, in concert with a modulated HIV-specific CD4 T cell response that maintains low numbers of HIV targets in mucosal tissue, while providing adequate help for a strong adaptive response. Moreover, we postulate that such a potent and balanced vaccine response will, in the context of active latency reversing agents, reduce viral reservoirs and thus maintain suppression of virus replication following cessation of highly active antiretroviral therapy. The approaches in FOCUS 1, aimed at understanding the mechanisms of vaccine protection, will utilize state of the art adjuvants coupled with native trimeric Env immunogens to induce and mechanistically dissect strong durable humoral responses. In addition, we aim to fully characterize and harness a novel population of tissue resident CD8 T cells to effectively synergize with the humoral immune response in providing protection from SHIV challenge. Because recent data suggest that SIV/HIV specific mucosal CD4 T cells could enhance infection, we will also explore the potential for modulating the susceptibility of these cells to enhance protection. In FOCUS 2, aimed at defining mechanisms of reservoir eradication, we will utilize novel latency reversing agents and immunostimulants to define an optimal viral reactivation program, and then will combine these with the optimized vaccine approaches defined in FOCUS 1 to explore the potential of this combination to yield a sustained suppression of virus replication following withdrawal of highly active antiretroviral therapy. These experimental approaches will be supported by an effective Operations and Management Support component and five state of the art Scientific Research Support Cores in order to fully characterize the magnitude, function, specificity and repertoire of the humoral response. Single cell analytics and transcriptomics will also support characterization of innate and adaptive signals at the cellular level.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection
  • 批准号:
    10462362
  • 项目类别:
  • 资助金额:
    $581.44万
  • 财政年份:
    2022
  • 负责人:
    Rama Rao Amara
  • 依托单位:
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection
  • 批准号:
    10618319
  • 项目类别:
  • 资助金额:
    $871.33万
  • 财政年份:
    2022
  • 负责人:
    Rama Rao Amara
  • 依托单位:
Correlates of protective immunity to HCV and rational vaccine design: Project 3
  • 批准号:
    10393619
  • 项目类别:
  • 资助金额:
    $40.81万
  • 财政年份:
    2021
  • 负责人:
    Rama Rao Amara
  • 依托单位:
Correlates of protective immunity to HCV and rational vaccine design: Project 3
  • 批准号:
    10205769
  • 项目类别:
  • 资助金额:
    $69.27万
  • 财政年份:
    2021
  • 负责人:
    Rama Rao Amara
  • 依托单位:
海外基金